Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Search
Medicines Law & Policy
Research and resources on intellectual property and health
Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Tag: The Netherlands
Remdesivir developed country price announced
Ellen 't Hoen
-
June 30, 2020
Medicines Law & Policy’s director, Ellen ’t Hoen, receives high Netherlands...
Kaitlin Mara
-
April 24, 2020
Dutch Minister of Health writes open letter to pharma, threatens to...
Ellen 't Hoen
-
August 28, 2019
Strong call for transparency on medicine prices, cost of R&D at...
Ellen 't Hoen
-
April 19, 2019
Humiragate: AbbVie’s desperate attempts to keep its monopoly
Ellen 't Hoen
-
March 27, 2019
Faced with unreasonable medicines prices, the Netherlands introduces pharmacy exemption in...
Ellen 't Hoen
-
February 22, 2019
Cystic Fibrosis Medicines Wars in Europe
Ellen 't Hoen
-
February 3, 2019
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
This work is licensed under Creative Commons.